German Biotech's $6.5M Seed Targets Next-Generation Heart Therapies

Jan de Vries · 2026-08-28

A fresh player just entered the European biotech arena with a focused mission and fresh capital. Revier Therapeutics, launching from the historic university city of Heidelberg, Germany, has officially opened its doors and secured a $6.5 million Seed round to chase down new treatments for cardiometabolic diseases. Think about heart failure and cardiovascular disease for a second. Despite all our medical advances, millions of people are still stuck with limited options. That's the gap Revier is aiming to fill, and a consortium of investors believes they can do it. ### The Funding and The Backers The $6.5 million seed financing was led by the KHAN Technology Transfer Fund II. They weren't alone, though. The round saw participation from High-Tech Gründerfonds (HTGF), VORNvc, and a group of private investors coordinated through Revier Invest Heidelberg. It's a classic example of regional European deep-tech support coming together to back a promising science story. The coalition was spearheaded by local business developer Daniel Stern, showing how vital those community networks can be for getting a startup off the ground. ### A New Approach to an Old Problem So, what's the big idea? Revier is going after a specific class of enzymes called class IIa histone deacetylases, or HDACs. Here's the simple version: these enzymes play a key role in some serious diseases, but previous attempts to target them were too broad, like using a sledgehammer when you need a scalpel. First-generation HDAC inhibitors hit multiple enzyme classes, which often led to nasty side effects that limited how much medicine a patient could tolerate. Revier's team believes they've designed a more precise tool. Their orally available small molecules are engineered to selectively inhibit just the class IIa HDACs. The goal is to block the disease-causing activity without messing up the healthy biological functions these enzymes perform. It's a delicate balance. As Prof. Johannes Backs, MD, the company's scientific founder, put it: “This precise mode of action is designed to be therapeutically effective while maintaining a beneficial safety profile.” ### The Leadership and The Vision Leading the charge is Prof. Eva van Rooij, PhD, co-founder and CEO. She frames the challenge clearly. “Despite significant progress, millions of patients... still face limited targeted treatment options,” she notes. Her vision is to move beyond managing symptoms and instead tackle the underlying biology that drives these diseases. The company's initial focus is on two major conditions: - Heart failure with preserved ejection fraction (HFpEF) - Atherosclerotic cardiovascular disease (ASCVD) Their mission is to translate the potential of class IIa HDAC inhibition from a compelling scientific concept into a real pipeline of novel therapies. They want to get their lead programs into clinical testing rapidly, creating value for patients and the healthcare system. ### Why Investors Are Betting on Revier Michael Hamacher, PhD, of lead investor KHAN, highlighted the combination he found compelling. He pointed to Revier's “differentiated class IIa HDAC strategy” which could “unlock the therapeutic promise of HDAC biology” while avoiding the pitfalls of older approaches. Paired with what he calls an “exceptional leadership team and deep scientific expertise,” the company has a shot at reshaping patient care. The capital from this seed round has a clear job. It's earmarked to push their preclinical pipeline forward, focusing on that lead HFpEF program and a second one for ASCVD. The money will also help them build out the operational, scientific, and clinical teams needed to transition from a research-stage startup to a clinical-stage company. It's a significant step for the European biotech ecosystem. Another innovative team, backed by specialist investors, is taking aim at some of healthcare's most persistent challenges. The path from lab to clinic is long and fraught with risk, but with $6.5 million in the bank and a clear scientific strategy, Revier Therapeutics is now officially on its way.